The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
The IMforte trial showed improved progression-free survival and overall survival with lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer. The trial's primary analysis results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback